GSK has taken another step towards rebuilding its respiratory pipeline with a $1.4 billion agreement to buy Aiolos Bio and its lead drug AIO-001 for asthma and other indications. The deal ...
Hosted on MSN2mon
UK-based Verdiva launches with $410m and an oral GLP-1RA candidateKhurem Farooq, previously CEO of Aiolos Bio and Gyroscope Therapeutics, has been appointed as Verdiva's CEO, supported by a leadership team that includes senior executives from Aiolos Bio and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback